Dear members of AANI
Kindly post any interesting articles or journals/ links in the field of allergy & asthma in this forum/section. All our members will benefit from it.
yours sincerely,
moderator AANI blogsite.
hi guys we proved that ours is best batch and got 100% results. we continue like this and keep in touch. we meet on august 18th bye
ReplyDeleteDr.t.r.r.krishna
Thanks Dr.Krishna for the information. Do keep in touch and please ask all the members to be active in our AANI blogsite
ReplyDeletebye,
Moderator AANI blogsite
Beta-Blockers May Benefit Patients with COPD
ReplyDeleteBeta-blockers, long withheld from patients with chronic obstructive pulmonary disease over concerns that they would worsen symptoms, actually seem to lessen mortality and exacerbations, according to an Archives of Internal Medicine study.
Researchers followed some 2200 patients (average age, 65) in the Netherlands for 7 years; all either had COPD at study entry or developed it over the course of the study. Patients taking beta-blockers were about a third less likely to die during the study and about a quarter less likely to have a COPD exacerbation.
Editorialists call for confirmation in a randomized trial and, pending that, say clinicians have a rationale for using beta-blockers "cautiously" in their patients with COPD and a coexisting heart condition.
What are you allergic to in your clinical practice :)
ReplyDeleteTop Ten Things I Don't Like About Being An Allergist
Gary Stadtmauer, MD, Allergy & Clinical Immunology, 07:47PM May 21, 2010
10. The seasonal aspect of allergy: Crazy busy followed by slow
9. We're not dermatologists, but people think we are or that any rash is an allergy
8. Unscrupulous "colleagues" who give us a bad reputation
7. Lack of respect by physicians in other specialties: OK we're not neurosurgeons but we do help people
6. The Town-Gown Divide: Differences, perceived or real, between academic allergists and those in the community
5. Pruritus
4. Urticaria
3. Chronic Urticaria
2. Chronic Idiopathic Urticaria
1. HIVES HIVES HIVES
Maternal skin-prick test reactivity accompanied
ReplyDeleteby allergic disease may increase infant vulnerability
to sensitization. Breastfeeding by atopic mothers increases
the likelihood of sensitization in infants. Probiotics
provide protection from sensitization in infants at
high risk.this article is taken from american academy of pediatrics
Age at First Introduction of Cow Milk
ReplyDeleteProducts and Other Food Products in Relation
to Infant Atopic Manifestations in the First 2
Years of Life: The KOALA Birth Cohort Study.
CONCLUSIONS. Delaying the introduction of cow’s milk
products or other food products may not be favorable for
preventing the development of atopy.
In giving advice to “allergic families,”
we used to think that it was a good idea to keep children
clean, away from pets, and to delay the introduction of
“highly allergenic” foods such as cow’s milk. Were we
wrong on all counts? There are many confounders when
evaluating the relationship between early introduction
of food products to infants and later development of
atopy. The authors of this article used several statistical.approaches to account for the main confounders, including
breastfeeding, family history, and, importantly, reverse
causation. Although it is difficult to absolutely
exclude reverse causation, this authors suggested that
delayed introduction of milk was associated with increased
eczema. Because of studies such as this one, the
focus has shifted away from the delayed introduction of
cow’s milk protein and other food products as a means to
decrease the risk of developing atopy. These findings
provide a rationale for conducting interventional studies
to determine whether early introduction of milk and
other foods will actually help to prevent food allergies.
THIS ARTICLE WAS PUBLISHED AAP.
Epidemiologic associations between viral lower respiratory infections (LRIs) and asthma in later childhood are well known. However, the question of whether such infections cause asthma or unmask asthma in a susceptible host has still not been settled. Most early evidence centered on the role of the respiratory syncytial virus; however, recent studies highlight a potential role for human rhinovirus as a risk factor for asthma. The links between early-life viral LRI and subsequent asthma are generally via wheeze; however, the presence of wheeze does not give any information about why the child is wheezing. Wheeze in early life is, at best, a fuzzy phenotype and not specific for subsequent asthma. The risk of asthma after viral LRI is increased in the presence of allergic sensitization in early life and if the infection is more severe. Atopy-associated mechanisms also appear to be involved in viral-induced acute exacerbations of asthma, especially in prolonging symptomatology after the virus has been cleared from the lungs. Breaking the nexus between viral respiratory infections and asthma may be possible with interventions designed to inhibit atopy-related effectors mechanisms from participating in the host response to respiratory viral infections.
ReplyDeleteJACI JUNE 2010
We were
ReplyDeleteable to show that VitD insufficiency in childhood asthma is
common and similar to that seen in the general population. We
found significant correlations between several markers of atopy
and lung function with VitD levels. Our study involved a high
number of oral steroid2dependent asthmatic patients and demonstrated
significant correlations between inhaled steroid use,
oral steroid use, and total steroid dose with VitD levels. This
finding supports our laboratory findings that VitD enhances the
anti-inflammatory effects of glucocorticoids. These findings have
important implications on potential future directions in asthma
research. First, these findings should be confirmed in a prospective
fashion that involves the generation of an efficient multivariate
model. Second, further research should be directed at the use
of VitD supplementation as a potential steroid-sparing agent in
patients with moderate-to-severe persistent asthma, as well as a
modifier of asthma disease severity.
jaci. may 2010
Oral Corticosteroids as Effective as Intravenous Dosing in COPD Exacerbations
ReplyDeleteAlthough given at lower doses, oral corticosteroids provide the same outcomes in acute exacerbations of chronic obstructive pulmonary disease (COPD) as higher intravenous doses, according to a study in JAMA.
Despite guidelines recommending use of the low-dose oral route, researchers found that the higher-dose intravenous route was used initially in 92% of some 80,000 patients admitted to over 400 U.S. hospitals. The primary outcome measure — a composite of the need for mechanical ventilation after the second hospital day, death during hospitalization, or readmission for COPD within 30 days — was no worse in orally treated patients.
The authors conclude that the initial use of high-dose intravenous therapy "does not appear to be associated with any measurable clinical benefit," and has the added dangers associated with intravenous therapy as well as higher costs. Editorialists say that the results "are sufficient to take action to change practice now."
JAMA article
Use of 2 Nasal Sprays Combined Relieves Seasonal Allergic Rhinitis Nasal Congestion: Presented at EAACI
ReplyDeleteBy Sara Freeman
LONDON -- June 11, 2010 -- The daily combined use of 2 nasal sprays, one containing an inhaled nasal steroid (INS) and the other containing a decongestant, can give significant relief from the nasal congestion experienced by people with seasonal allergic rhinitis (SAR), according to a study presented here at the 29th Congress of the European Academy of Allergy and Clinical Immunology (EAACI).
Individually, mometasone furoate and oxymetazoline have demonstrated efficacy for the treatment of SAR, but their use in combination has not been well studied, said William Berger, MD, University of California, Irvine, Irvine, California, on June 7.
"Two attributes cited by patients as being important to them are 24-hour efficacy and rapid onset of action," Dr. Berger observed. Whereas mometasone furoate has been shown to provide continued relief from rhinoconjunctivitis through the day, oxymetazoline is known to have a fast onset of action.
Dr. Berger presented the findings of a phase 2, single-blind, placebo-controlled study that assessed the efficacy of 1 spray per nostril of INS 200 mcg daily combined with 1 or 3 daily sprays per nostril of the decongestant (0.05%) versus placebo.
A total of 426 patients were studied, with 145 randomised to INS plus 1 spray of oxymetazoline, 139 to INS plus 3 sprays of the decongestant, and 142 to placebo. Treatment was continued for at least 2 weeks.
Nasal congestion was assessed via instantaneous and reflective patient report and total nasal symptom scores (TNSS).
"Both mometasone furoate and oxymetazoline once-daily combinations were significantly superior to placebo in reducing nasal congestion severity and composite TNSS in subjects with SAR," Dr. Berger said.
"Other than the first 15-minute area-under-the-curve nasal congestion score, all outcomes were statistically similar. In other words, 1 spray of oxymetazoline versus 3 sprays in combination with mometasone showed significant improvement over placebo," he added.
Despite the positive findings, a commercial product containing both mometasone furoate and oxymetazoline will probably not be developed right away, Dr. Berger said, but clinicians could consider the joint use of INS with the decongestant in suitable patients.
Funding for this study was provided by the Schering Corporation, a subsidiary of Merck & Co. Inc.
[Presentation title: Concomitant Once-Daily Administration of Mometasone Furoate Nasal Spray With One Spray and Three Sprays of Oxymetazoline Is Effective for the Treatment of Subjects With Seasonal Allergic Rhinitis. Abstract 374]
The news letter brings good news. Untiring efforts of Dr PK has brought this about. Looking forward to buying allergen kits in India...and ofcourse doing the voluntary work too! Anybody accessed the japi website?
ReplyDeletecongrats to your batch. but ti think the first batch had 100% results too, correct me if i am wrong. Ofcourse tthat is not to say you are not the best batch. I am from the second batch, Radhika thappeta's batchmate. Madhu Bashini
ReplyDeleteHi Dr.Madhu, Welcome & thanks for joining AANI blogsite. Hope u will have a good & useful time blogging in our own AANI blog site. Also please tell all ur batchmates to join our AANI community.
ReplyDeleteWith regards,
AANI blogsite moderator.